# EDGAR Filing Document

**Accession Number:** 0001870121
**File Stem:** 0001628280-26-023356
**Filing Date:** 2026-4
**Character Count:** 9824
**Document Hash:** dc4f7f545d595dcbf13714048971db6d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-26-023356.hdr.sgml**: 20260402

**ACCESSION NUMBER**: 0001628280-26-023356

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260402

**DATE AS OF CHANGE**: 20260402

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Twitty Christopher
- **CENTRAL INDEX KEY:** 0001870121

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42009
- **FILM NUMBER:** 26835989

**MAIL ADDRESS:**
- **STREET 1:** 100 SOMERSET CORPORATE BLVD., 2ND FLOOR
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Skye Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001516551
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 450692882
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 11250 EL CAMINO REAL, SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 410-0266

**MAIL ADDRESS:**
- **STREET 1:** 11250 EL CAMINO REAL, SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Emerald Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20190325

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Nemus Bioscience, Inc.
- **DATE OF NAME CHANGE:** 20141030

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LOAD GUARD LOGISTICS, INC.
- **DATE OF NAME CHANGE:** 20121107

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Twitty Christopher<br><sub>(Last) (First) (Middle)</sub><br>11250 EL CAMINO REAL, SUITE 100<br><sub>(Street)</sub><br>SAN DIEGO, CA 92130<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-03-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Scientific Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Skye Bioscience, Inc. [ SKYE ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Buy) | 0.615<sup>(1)</sup> | 2026-03-31 |  | A |  | 17004 |  | <sup>(2)</sup> | 2033-09-29 | Common Stock | 17004 | <sup>(3)</sup> | 17004 | D |  |
| Stock Option (Right to Buy) | $3.50 | 2026-03-31 |  | D |  |  | 17004 | <sup>(2)</sup> | 2033-09-29 | Common Stock | 17004 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | 0.61<sup>(1)</sup> | 2026-03-31 |  | A |  | 75000 |  | <sup>(4)</sup> | 2034-02-28 | Common Stock | 75000 | <sup>(3)</sup> | 75000 | D |  |
| Stock Option (Right to Buy) | $14.56 | 2026-03-31 |  | D |  |  | 75000 | <sup>(4)</sup> | 2034-02-28 | Common Stock | 75000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | 0.615<sup>(1)</sup> | 2026-03-31 |  | A |  | 7100 |  | <sup>(5)</sup> | 2033-11-06 | Common Stock | 7100 | <sup>(3)</sup> | 7100 | D |  |
| Stock Option (Right to Buy) | $3.50 | 2026-03-31 |  | D |  |  | 7100 | <sup>(5)</sup> | 2033-11-06 | Common Stock | 7100 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | 0.615<sup>(1)</sup> | 2026-03-31 |  | A |  | 200000 |  | <sup>(6)</sup> | 2034-10-28 | Common Stock | 200000 | <sup>(3)</sup> | 200000 | D |  |
| Stock Option (Right to Buy) | $5.15 | 2026-03-31 |  | D |  |  | 200000 | <sup>(6)</sup> | 2034-10-28 | Common Stock | 200000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | 0.615<sup>(1)</sup> | 2026-03-31 |  | A |  | 150000 |  | <sup>(7)</sup> | 2035-02-24 | Common Stock | 150000 | <sup>(3)</sup> | 150000 | D |  |
| Stock Option (Right to Buy) | $2.89 | 2026-03-31 |  | D |  |  | 150000 | <sup>(7)</sup> | 2035-02-24 | Common Stock | 150000 | <sup>(3)</sup> | 0 | D |  |
| Stock Option (Right to Buy) | 0.615<sup>(1)</sup> | 2026-03-31 |  | A |  | 12000 |  | <sup>(8)</sup> | 2033-01-05 | Common Stock | 12000 | <sup>(3)</sup> | 12000 | D |  |
| Stock Option (Right to Buy) | $4.25 | 2026-03-31 |  | D |  |  | 12000 | <sup>(8)</sup> | 2033-01-05 | Common Stock | 12000 | <sup>(3)</sup> | 0 | D |  |

---

### Footnotes:

(1) The exercise price of the stock option is $0.615 per share, representing the closing price of the Issuer's common stock on the date of the repricing.

(2) The stock option vests in equal monthly installments over the four year period beginning on August 24, 2023. The grant date for the stock option is August 25, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

(3) On March 31, 2026, the board of directors of the Issuer approved the one-time repricing of the stock option effective as of March 31, 2026. Except as described in footnote 1, all other terms of the stock option remain unchanged.

(4) The stock option vests in equal monthly installments over the four year period beginning February 29, 2024. The grant date for the stock option is February 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

(5) The stock option vests in equal monthly installments over the four year period beginning August 24, 2023. The grant date for the stock option is November 6, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

(6) The stock option vests in equal monthly installments over the four year period beginning October 28, 2024. The grant date for the stock option is October 28, 2024. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

(7) The stock option is fully vested. Due to an administrative error, the Form 3 filed by the Reporting Person on April 25, 2025 inadvertently stated that the stock option vests in equal monthly installments over the one year period beginning February 21, 2025.  In fact, the stock option vests in equal monthly installments over the four year period beginning February 24, 2025.

(8) The stock option vests 25% on December 8, 2023 and 1/48th monthly thereafter. The grant date for the stock option is January 5, 2023. Upon a change in control of the Issuer, 100% of the stock option will become fully vested.

**Signature:** /s/ Punit S. Dhillon, as Attorney-in-Fact for Christopher Twitty  
**Date:** 2026-04-02

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**